Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

Thermo Fisher Scientific has agreed to acquire Clario Holdings for nearly $8.9 billion, in a deal that would give it control ...

Kennedy suggested the requirement for CES is one reason why the US is lagging behind other parts of the world in the rollout ...

And this is where targeted radiotherapeutics come in. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Inizio brings in seasoned pharma exec for top job. A new chapter begins at Inizio with the appointment of Ryan Quigley as CEO ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

Inherited cardiac conditions (ICCs) can lead to heart failure, and fewer than half of all people diagnosed with heart failure ...

Prostate Cancer UK started a £42 million ($55 million), large-scale study called TRANSFORM last year to test that MRI-refined ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...

Eli Lilly and tech giant NVIDIA have joined forces on an ambitious plan – building the most powerful AI-powered supercomputer ...